Due to co-expression of CD133 and CD44 in some cases, we divided these HCC patients into four groups— CD44low/CD133low, CD44low/CD133high, CD44high/CD133low and CD44high/CD133high—to analyze the prognostic effects of these two factors. The gene discussed is PROM1; the disease is hepatocellular carcinoma.